OncoMatch/Clinical Trials/NCT07315828
Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery
Is NCT07315828 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies Indocyanine Green for giant cell tumor of bone.
Treatment: Indocyanine Green — This study evaluates the diagnostic accuracy of Indocyanine Green (ICG) fluorescence imaging in visualizing residual lesions of Giant Cell Tumor of Bone (GCTB) in the tumor cavity during surgery. Patients diagnosed with GCTB will receive an intravenous injection of ICG prior to the operation to label tumor tissues. During the procedure, surgeons will use a near-infrared fluorescence imaging system to visualize the tumor cavity and identify potential residual lesions after standard curettage. The study aims to determine the sensitivity, specificity, positive predictive value, and negative predictive value of ICG fluorescence imaging by comparing the intraoperative fluorescence findings with the final pathological results of the validation samples.
Check if I qualifyEligibility summary
For patients with giant cell tumor of bone.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify